Healthcare

Pfizer Inc. (NYSE: PFE) achieved second-quarter revenues of $15 billion, a 3% increase compared to the previous year, and surpassed analyst expectations. This result led the pharmaceutical giant to adjust its 2026 revenue guidance upward by $500 million, now targeting between $60.5 billion and …

Novo Nordisk A/S has raised its forecast, but the stock has come under pressure, reflecting a growing concern regarding its viability in the obesity treatment market. Following a reported earnings per share (EPS) of $6.63 for the quarter ended March 31, exceeding consensus estimates …

Nuvectis Pharma, Inc. (NASDAQ: NVCT) enhanced its financial footing by successfully raising $115 million in a follow-on offering completed in July 2026. This substantial funding lowers liquidity challenges and supports its urgent development agenda, particularly for its lead drug candidate, ciprocopan (NXP100), which has …

Odyssey Therapeutics, Inc. reported a substantial net loss of $52.8 million in its second quarter ended June 30, 2026, significantly greater than the $41.2 million loss recorded during the same period in the previous year. The reported earnings per share (EPS) of $-6.77 also …

Legislative reforms across various jurisdictions are facilitating easier access to Medical Aid in Dying for terminally ill individuals. These changes introduce specific eligibility conditions that streamline the process, allowing patients to make important end-of-life decisions more autonomously. As more states adopt similar measures, the …

This marks a critical moment for the company as it navigates a challenging financial environment, especially when compared to a healthy year-to-date performance.

The loss widened compared with the prior year, and the company fell short of consensus expectations. Net loss for the quarter amounted to $2.6 million, while unrestricted cash and marketable securities stood at $23.3 million, up from $14.9 million at the close of 2025.